Clinical Trial Update: Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome [Phase 2, Phase 3]

View source ↗

Summary

Open-label rollover study of PBI 4050 in Alström syndrome was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alström Syndrome

Drugs mentioned

• PBI-4050

Snippet

Sponsor: Liminal BioSciences Ltd. | Conditions: Alström Syndrome | Phase 2, Phase 3 | Status: TERMINATED